José Manuel A. L.
- Country
- Spain
- Department
- 2104: Oftalmología
Research Overview
- Open-Label Evaluation of VRDN-001 in Non-Responders with Thyroid Eye Disease from VRDN-001-101 and VRDN-001-301 Studies
- Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of Oxymetazoline Hydrochloride 0.1% Eye Drops for Acquired Blepharoptosis Treatment
- Evaluation of Human (scFv)2-Fab Fusion Protein Against CD40L in Moderate-to-Severe Thyroid Eye Disease: An Open-Label, Long-Term Follow-Up Study
Data & Insights
Has run more than one trial at 38 of 88 partner sites.
Specializations
Thyroid Eye Disease Management
This investigator specializes in the clinical evaluation of novel therapeutic approaches for thyroid eye disease (TED), with particular focus on investigating both intravenous and subcutaneous treatment modalities.
- Active TED therapeutics
- Novel biological treatments
- Long-term disease management
The research encompasses various severity levels of TED, from moderate to severe manifestations.
Ophthalmological Disorders
The investigator conducts research in the treatment of acquired blepharoptosis, exploring innovative topical treatments for this eye condition.
- Eyelid disorders
- Topical ophthalmic treatments
- Visual function improvement
The focus includes evaluating new therapeutic options for patients with eyelid mobility disorders.
Treatment Response Assessment
Expertise in evaluating therapeutic efficacy and monitoring treatment responses in ocular conditions, with particular attention to non-responder management strategies.
- Response monitoring
- Alternative treatment approaches
- Long-term outcome assessment
The investigator specializes in developing treatment strategies for patients who don't respond to initial therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.